448
A 69-year-old white female whose anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk) presented to an anticoagulation clinic with a critically elevated INR of greater than 12.3 after a dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week.
 69-year-old white female: Subject; 69-year-old: Subject.Age; white: Subject.Race; female: Subject.Gender; elevated INR of greater than 12.3: Effect; anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk): Treatment; dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week: Treatment; extended-release niacin: Treatment.Drug; warfarin: Treatment.Drug; 1000 mg: Treatment.Dosage; 2.5 mg: Treatment.Dosage; daily: Treatment.Freq; daily: Treatment.Freq; extended-release niacin: Combination.Drug; warfarin: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 69-year-old white female: Subject; 69-year-old: Subject.Age; white: Subject.Race; female: Subject.Gender; elevated INR of greater than 12.3: Effect; anticoagulation treatment had been stable for 18 months with warfarin 2.5 mg daily (17.5 mg/wk): Treatment; dose increase in extended-release niacin (Niaspan) from 500 mg to 1000 mg daily the previous week: Treatment; extended-release niacin: Treatment.Drug; warfarin: Treatment.Drug; 1000 mg: Treatment.Dosage; 2.5 mg: Treatment.Dosage; daily: Treatment.Freq; daily: Treatment.Freq; extended-release niacin: Combination.Drug; warfarin: Combination.Drug